Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Cancer Immunotherapy Linked To Increased Risk Of Rheumatologic Disorders



Due to the nature of immunotherapy treatments, researchers had previously only expected the drugs to exacerbate preexisting rheumatologic symptoms.

Share this!

Tweet: Researchers find link between immunotherapy and rheumatologic disorders http://ctt.ec/fVC6e+Researchers find connection between immunotherapy and rheumatologic disorders.

Tweet: 1.3% of patients receiving immunotherapy showed rheumatologic symptoms http://ctt.ec/P2YW3+1.3% of patients receiving immunotherapy showed rheumatologic symptoms.

June 28, 2016 | by Sarah Massey, M.Sc.

A recent study conducted by Johns Hopkins University researchers has found a connection between cancer immunotherapy treatments and an increased risk of developing rheumatologic disorders, such as arthritis. Due to the nature of immunotherapy treatments, researchers had previously only expected the drugs to exacerbate preexisting rheumatologic symptoms.

In the largest study of its kind to date, Johns Hopkins researchers found that between 2012 and 2016, 1.3 percent of patients receiving cancer immunotherapy reported suffering from a rheumatologic disease as a result. Based on a relatively small sample size of 13 patients, the researchers concluded that immunotherapy drugs used alone, or in combination with other treatments, could lead to a higher than normal risk of rheumatologic disorders.

“I don't think anyone is particularly surprised that rheumatologic disorders might be a complication of drugs that boost the immune system,” said Dr. Laura Cappelli, rheumatologist at the Johns Hopkins University School of Medicine, and an author on the study. According to Cappelli, the study may even have underestimated the number of cases of rheumatologic disorders, as symptoms such as mild joint pain may have gone undiagnosed.

The researchers say that further studies will need to be performed in order to confirm a causal link between immune checkpoint inhibitors and rheumatologic disorders. Cappelli is urging physicians and patients to consider both the potential benefits and risks of immunotherapy drugs before starting treatment, and to monitor for signs of rheumatologic symptoms so that action may be taken to limit joint damage.

All 13 patients treated at the Johns Hopkins Kimmel Cancer Center were receiving Bristol-Myers Squibb’s Yervoy (ipilimumab) or Opdivo (nivolumab), either alone or in combination. These patients developed symptoms consistent with arthritis, or with a combination of autoimmune symptoms including dry eyes and mouth, known as sicca syndrome.

“In 2015, our rheumatology clinic started getting more and more referrals from our oncology department to evaluate patients treated with immunotherapies,” said Cappelli. “And the patients we saw had very severe, highly inflammatory arthritis. They needed even higher doses of steroids to control their symptoms compared to what is needed in other forms of inflammatory arthritis, like rheumatoid arthritis.”

The researchers point out that clinical trials of the immunotherapy drugs found an increased risk of rheumatologic conditions such as inflammatory bowel diseases, lung inflammation, autoimmune thyroid disease and pituitary gland inflammation. Cappelli and her colleagues plan to continue to monitor the incidence of rheumatologic disease among immunotherapy patients, to try to identify what makes some patients more likely to develop these symptoms, compared to others.

Keywords: Cancer, Immunotherapy, Arthritis


Share this with your colleagues!

New PARP Inhibitor Drug Approved to Treat Women with Recurrent Ovarian Cancer

March 29, 2017 - The US Food and Drug Administration (FDA) has approved Zejula (niraparib) as a maintenance treatment for women with certain types of recurrent cancers, including epithelial ovarian, fallopian tube, and primary peritoneal cancer.

Featured In: Pharmaceutical News

Nektar’s Opioid Analgesic Meets Endpoints in Phase III Clinical Trial

March 28, 2017 - Nektar Therapeutics has announced that their opioid analgesic has met both its primary and secondary endpoint in a recent Phase III efficacy study.

Featured In: Clinical Trials News

Small Molecule May Disrupt Biofilm Formation on Implantable Medical Devices

March 28, 2017 - Researchers at Trinity College Dublin in Ireland have identified a small molecule capable of preventing bacterial biofilms from growing on medical implants.

Featured In: Medical Device News


Will Pharmaceutical Serialization Solve All of Our Drug Counterfeiting Problems?


Strategies for Deploying Innovative Solutions for Perimeter Security

Natural History vs. Registry Studies in Rare Disease

The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review

Combination Product Regulatory Requirement Complexities and the Impact of the 21st Century Cures Act

Copyright © 2016-2017 Honeycomb Worldwide Inc.